Advances in the Treatment of Multiple Sclerosis
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Neurologic Clinics
- Vol. 39 (1) , 21-33
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 52 references indexed in Scilit:
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisNew England Journal of Medicine, 2008
- Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trialAnnals of Neurology, 2007
- Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Interferon β-1a in primary progressive MSNeurology, 2003
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- Randomized controlled trial of interferon- beta-1a in secondary progressive MSNeurology, 2001
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993